• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Annals of Gastroenterological Surgery >Bevacizumab‐associated intestinal perforation and perioperative complications in patients receiving bevacizumab
【24h】

Bevacizumab‐associated intestinal perforation and perioperative complications in patients receiving bevacizumab

机译：贝伐单抗相关的肠穿孔和接受贝伐单抗患者的围手术期并发症

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Aim The purposes of this study are to present cases of emergency surgery in which gastrointestinal perforation occurred during bevacizumab administration, consider the indications for emergency surgery, and examine the safety of scheduled surgery after a washout period for bevacizumab. Methods (a) We retrospectively investigated seven patients who underwent emergency surgery for bevacizumab‐associated intestinal perforation. (b) We investigated 104 patients with advanced colorectal cancer treated with neoadjuvant therapy who underwent surgery from 2008 to 2018, retrospectively. Results (a) In the seven patients undergoing emergency surgery for gastrointestinal perforation, the median bevacizumab administration and washout periods were 16?weeks and 24?days, respectively. A stoma was created in all patients except in those who were not candidates. Two patients developed postoperative abdominal abscesses, and two patients died from perioperative sepsis and gastrointestinal bleeding, respectively; both of these patients had poor performance status. (b) In patients receiving bevacizumab (n?=?45) and patients treated with bevacizumab‐free regimens as neoadjuvant therapy (n?=?59), 31 and 52 patients received chemoradiotherapy, respectively. We found no correlation with postoperative complications with or without bevacizumab. Conclusion The surgical indications should be considered carefully in patients with gastrointestinal perforation secondary to bevacizumab administration. Meanwhile, after appropriate cessation time, scheduled surgery following bevacizumab administration is feasible.
机译：目的本研究的目的是呈现出疾病疾病发生的急诊手术病例，在Bevacizumab管理期间发生胃肠道穿孔，考虑急诊手术的适应症，并在Bevacizumab的冲洗期后检查预定手术的安全性。方法（a）我们回顾性地研究了患有贝伐单抗相关肠穿孔的急诊手术的七名患者。 （b）我们调查了104例患有Neoadjuvant癌症治疗的晚期结直肠癌，追溯到2018年至2018年接受手术治疗。结果（a）在胃肠道穿孔急诊手术中的七名患者中，中位数贝伐单抗管理和冲洗时间分别为16？周和24天。除了没有候选人的人之外，在所有患者中都会产生一种造香的造口。两名患者开发出术后腹部脓肿，两名患者分别从围手术期败血症和胃肠道出血中死亡;这两个患者的性能状况差。 （b）接受Bevacizumab（n？= 45）的患者，并且使用贝伐单抗方案治疗的患者作为Neoadjuvant治疗（n？=α59），31和52名患者接受了化学疗法。我们发现没有与术后并发症的相关性或没有贝伐单抗。结论外科适应症应仔细考虑患有嗜虫草酰胺的胃肠道穿孔患者。同时，在适当的停止时间后，贝伐单抗管理后的预定手术是可行的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号